Collagenase

(rINNM)

💊 Chemical information

Clostridiopeptidas; Clostridiopeptidase A; Clostridiopeptidasum A; Colagenasa; Klostridiopeptidaasi A.
CAS — 9001-12-1.
ATC Vet — QD03BA02.

💊 Profile

Collagenase is a proteolytic enzyme derived from the fermentation of Clostridium histolyticum and has the ability to break down collagen. Preparations containing collagenase are used topically for the debridement of dermal ulcers and burns, and possibly other necrotic lesions, to facilitate granulation and epithelialisation. It has also been given by injection into the intervertebral disc for chemonucleolysis in the treatment of lumbar disc herniation. Collagenase is under investigation for use in Dupuytren’s disease and

Peyronie’s disease.

Hypersensitivity reactions may occur. Local burning, erythema, and pain have been reported at the site of application. It has been suggested that debridement of infected wounds may increase the risk of bacteraemia and that patients should be watched for signs of systemic bacterial infection. The activity of collagenase may be reduced by antiseptics containing detergents, hexachlorophene, and heavy metal ions. Collagenase potency is expressed in units based on the amount of enzyme required to degrade a standard preparation of undenatured collagen.

Chemonucleolysis.

Collagenase has been studied as an alternative to chymopapain for chemonucleolysis because of the risk of anaphylaxis with the latter. Although early studies with collagenase reported benefit, there were also reports of back pain and muscle spasm.1 Collagenase was not as effective as chymopapain in a comparative study,2 and further study may be warranted before a firm recommendation can be made.
1. Brown MD. Update on chemonucleolysis. Spine 1996; 21 (24 suppl): 62S–68S
2. Wittenberg RH, et al. Five-year results from chemonucleolysis with chymopapain or collagenase: a prospective randomized study. Spine 2001; 26: 1835–41.

Dupuytren’s disease.

Collagenase has been reported to be of benefit in the treatment of Dupuytren’s contracture.1
1. Badalamente MA, Hurst LC. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren’s contracture. J Hand Surg (Am) 2007; 32: 767–74.

Peyronie’s disease.

Beneficial effects have been reported with intralesional collagenase in men with

Peyronie’s disease.

1-3
1. Gelbard MK, et al. The use of collagenase in the treatment of Peyronie’s disease. J Urol (Baltimore) 1985; 134: 280–3
2. Gelbard MK, et al. Collagenase versus placebo in the treatment of Peyronie’s disease: a double-blind study. J Urol (Baltimore) 1993; 149: 56–8
3. Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie’s disease: a prospective, single-center, non-placebo-controlled study. J Sex Med 2008; 5: 180–7.

💊 Preparations

Proprietary Preparations

Belg.: Iruxol Mono; Braz.: Iruxol Mono; Kollagenase; Canad.: Santyl†; Gr.: Iruxol Mono; Hong Kong: Iruxol Mono; Ital.: Noruxol; Neth.: Novuxol; Port.: Ulcerase; Switz.: Iruxol Mono; Turk.: Novuxol; USA: Santyl; Venez.: Iruxol Simplex. Multi-ingredient: Arg.: Iruxol; Braz.: Gyno Iruxol; Iruxol; Kollagenase com cloranfenicol; Cz.: Iruxol Mono; Fin.: Iruxol; Iruxol Mono; Ger.: Iruxol N†; Hung.: Iruxol Mono; Irl.: Iruxol Mono; Ital.: Iruxol; Malaysia: Iruxol Mono; Mex.: Ulcoderma; Rus.: Iruxol (Ируксол); S.Afr.: Iruxol Mono; Singapore: Iruxol Mono; Spain: Iruxol Mono; Iruxol Neo.
Published May 02, 2019.